Premium
Comparison of activin A and cell‐free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia
Author(s) -
Diesch Claude Henri,
Holzgreve Wolfgang,
Hahn Sinuhe,
Zhong Xiao Yan
Publication year - 2006
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.1606
Subject(s) - preeclampsia , cell free fetal dna , medicine , fetus , biomarker , endocrinology , adiponectin , pregnancy , prospective cohort study , andrology , biology , prenatal diagnosis , insulin resistance , biochemistry , genetics , insulin
Abstract Objectives We examined the concentration of activin A in a prospective manner before the clinical manifestation of preeclampsia and compared the data with those of cell‐free fetal DNA in the maternal plasma. Methods The levels of activin A were analysed by enzyme‐linked immunosorbent assay (ELISA) for pregnant women: (1) with preeclampsia ( n = 34) in the third‐trimester and normal controls ( n = 44); and (2) at‐risk of preeclampsia in the second‐trimester ( n = 15) as indicated by uterine artery Doppler and normal controls ( n = 68). Correlation between activin A level and cell‐free fetal DNA level was examined using the Spearman rank test. Results The level of plasma activin A was significantly higher in the preeclamptic samples (12.056 vs 7.068 ng/mL, p = 0.000). The increase in the activin A concentration was observed prior to the onset of preeclampsia (3.483 vs 1.324 ng/mL, p = 0.000). This increase in activin A correlated significantly with the increased level of cell‐free fetal DNA, in the maternal circulation prior to the onset of preeclampsia ( r = 0.977, p = 0.000). Conclusion Our data suggest that circulatory activin A could be an independent biomarker for the early identification and monitoring of preeclampsia. Copyright © 2006 John Wiley & Sons, Ltd.